MeiraGTx Q4 2024 Earnings Report

MeiraGTx EPS Results

• Actual EPS: -$0.50
• Consensus EPS: -$0.48
• Beat/Miss: Missed by -$0.02
• One Year Ago EPS: N/A

MeiraGTx Revenue Results

• Actual Revenue: $21.39 million
• Expected Revenue: $1.50 million
• Beat/Miss: Beat by +$19.89 million
• YoY Revenue Growth: N/A

MeiraGTx Announcement Details

• Quarter: Q4 2024
• Date: 3/13/2025
• Time: Before Market Opens
• Conference Call Date: Wednesday, March 12, 2025
• Conference Call Time: 7:00PM ET

MeiraGTx (NASDAQ:MGTX) is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders. MeiraGTx has established an end-to-end platform encompassing vector design, process development, and manufacturing scale-up, with capabilities housed in facilities across the United Kingdom and the United States. This integrated approach aims to accelerate the transition from preclinical research to clinical trials and, ultimately, patient access.

MeiraGTx completed its initial public offering on the Nasdaq in April 2018 and operates research laboratories in London alongside a manufacturing and clinical operations center in the New York metropolitan area. The company’s leadership team comprises industry veterans with extensive experience in gene therapy development, regulatory affairs and commercialization. MeiraGTx continues to advance its clinical programs in collaboration with academic institutions and contract research organizations, targeting global patient populations in need of novel therapeutic options.